Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial

Breast Cancer Research and Treatment

Volumn 116, Issue 2, 2009, Pages 371-378

  Ellis, Matthew J ^a   Miller, William R ^b   Tao, Yu ^a   Evans, Dean B ^c   Chaudri Ross, Hilary A ^c   Miki, Yasuhiro ^d   Suzuki, Takashi ^d   Sasano, Hironobu ^d  

^a USA   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

^d TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aromatase; Letrozole; Neoadjuvant endocrine therapy; Tamoxifen

Indexed keywords

AROMATASE; BIOLOGICAL MARKER; ESTROGEN RECEPTOR; KI 67 ANTIGEN; LETROZOLE; TAMOXIFEN;

ADJUVANT THERAPY; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CELL LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; NEOADJUVANT THERAPY; NITRILES; PROGNOSIS; RECEPTORS, ESTROGEN; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 67649230033     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0161-8     Document Type: Article

References (21)

1. Reed MJ (1994) The role of aromatase in breast tumors. Breast Cancer Res Treat 30(1):7-17. doi:10.1007/BF00682737
2. Miller WR (2006) Aromatase inhibitors and breast cancer. Minerva Endocrinol 31(1):27-46
3. Miller WR, Hawkins RA, Forrest AP (1982) Significance of aromatase activity in human breast cancer. Cancer Res 42(8 Suppl):3365s-3368s
4. Miller WR, Anderson TJ, Jack WJ (1990) Relationship between tumour aromatase activity, tumour characteristics and response to therapy. J Steroid Biochem Mol Biol 37(6):1055-1059. doi: 10.1016/0960-0760(90)90465-W
5. Miller WR (1991) Aromatase activity in breast tissue. J Steroid Biochem Mol Biol 39(5B):783-790. doi:10.1016/0960-0760(91) 90026-2
6. Lipton A, Santen RJ, Santner SJ, Harvey HA, Sanders SI, Matthews YL (1992) Prognostic value of breast cancer aromatase. Cancer 70(7):1951-1955. doi :10.1002/1097-0142(19921001)70: 7\1951::AID-CNCR2820700723[3.0.CO;2
7. Esteban JM, Warsi Z, Haniu M, Hall P, Shively JE, Chen S (1992) Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation. Am J Pathol 140(2):337-343
8. Miki Y, Suzuki T, Sasano H (2007) Controversies of aromatase localization in human breast cancer-stromal versus parenchymal cells. J Steroid Biochem Mol Biol 106(1-5):97-101
9. Sasano H, Anderson TJ, Silverberg SG, Santen RJ, Conway M, Edwards DP, Krause A, Bhatnagar AS, Evans DB, Miller WR (2005) The validation of new aromatase monoclonal antibodies for immunohistochemistry-a correlation with biochemical activities in 46 cases of breast cancer. J Steroid Biochem Mol Biol 95(1-5):35-39
10. Miki Y, Suzuki T, Tazawa C, Yamaguchi Y, Kitada K, Honma S et al (2007) Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Res 67(8):3945-3954. doi:10.1158/ 0008-5472.CAN-06-3105
11. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J et al (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12(11):1527- 1532. doi:10.1023/A:1013128213451
12. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2- positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19(18): 3808-3816
13. Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Janicke F et al (2003) Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63(19):6523-6531
14. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AJ et al (2008) Outcome prediction for estrogen receptor-positive breast cancer based on post neoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100(19): (in press)
15. Miller WR, Forrest AP (1974) Oestradiol synthesis by a human breast carcinoma. Lancet 2(7885):866-868. doi:10.1016/S0140- 6736(74)91202-1
16. Reed MJ, Aherne GW, Ghilchik MW, Patel S, Chakraborty J (1991) Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues. Int J Cancer 49(4):562-
17. doi:10.1002/ijc.2910490415
18. Miller WR (1997) Uptake and synthesis of steroid hormones by the breast. Endocr Relat Cancer 4:307-311
19. Bezwoda WR, Mansoor N, Dansey R, Esser JD (1987) Aromatisation of androstenedione by human breast cancer tissue: correlation with hormone receptor activity and possible biologic significance. Oncology 44(1):30-33
20. Miller WR, Anderson TJ, Evans DB, Krause A, Hampton G, Dixon JM (2003) An integrated view of aromatase and its inhibition. J Steroid Biochem Mol Biol 86(3-5):413-421. doi: 10.1016/S0960-0760(03)00352-2
21. Miller WR, Dixon JM (2002) Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 9(2 Suppl): 9-15